Pekin Hardy Strauss’s Iovance Biotherapeutics IOVA Stock Holding History

Pekin Hardy Strauss’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,050	Closed	-$19K	–	421
2025 Q2	$19K	Sell	11,050 -17,000	-61%	-$42.3K	﹤0.01%	360
2025 Q1	$93.4K	Hold	28,050	–	–	0.01%	348
2024 Q4	$208K	Sell	28,050 -5,000	-15%	-$46.3K	0.03%	331
2024 Q3	$310K	Sell	33,050 -2,000	-6%	-$18.9K	0.04%	287
2024 Q2	$281K	Sell	35,050 -8,000	-19%	-$85.7K	0.04%	267
2024 Q1	$638K	Sell	43,050 -9,950	-19%	-$116K	0.09%	193
2023 Q4	$431K	Sell	53,000 -3,000	-5%	-$15.7K	0.06%	210
2023 Q3	$255K	Buy	+56,000	New	+$366K	0.04%	249

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pekin Hardy Strauss's IOVA Position: Q3 2025 in Review

Pekin Hardy Strauss sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 11,050 shares — an estimated $19K sold.

Pekin Hardy Strauss first reported a position in IOVA in Q3 2023 and held it in 8 quarters. The position peaked at $638K in Q1 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

Pekin Hardy Strauss reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
Pekin Hardy Strauss sold 11,050 Iovance Biotherapeutics shares in Q3 2025, an estimated $19K.
Pekin Hardy Strauss first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 8 quarters.
Pekin Hardy Strauss's Iovance Biotherapeutics position peaked at $638K in Q1 2024.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Pekin Hardy Strauss's 13F filing for Q3 2025, filed 10 Nov 2025.